Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis

Journal of Drugs in Dermatology

Volumn 9, Issue 4, 2010, Pages 372-376

  Taneja, Charu ^a   Antaya, Richard J ^b   Berger, Ariel ^a   Marshall, Thomas S ^c   Seifeldin, Raafat ^c   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIMECROLIMUS; TACROLIMUS; DRUG DERIVATIVE;

ARTICLE; ATOPIC DERMATITIS; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG RESPONSE; HUMAN; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; OINTMENT;

ADULT; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; HUMANS; OINTMENTS; TACROLIMUS;

EID: 77953627672     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Paller AD, Lebwohl M, Fleischer AB, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52:810-822. (Pubitemid 40614645)
2. Delea TE, Gokhale M, Makin C, et al. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. J Manag Care Pharm. 2007;13:349-359. (Pubitemid 46964282)
3. Abramovits W, Boguniewicz M, Prendergast MM, et al. Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis. J Med Econ. 2003;6:1-14. (Pubitemid 37168820)
4. Ellis CN, Kahler KH, Grueger J, Chang J. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol. 2006;7:133-139.
5. Hjelmgren J, Svensson A, Jorgensen ET, et al. Cost-effectiveness of tacrolimus ointment versus standard treatment in patients with moderate and severe atopic dermatitis: A health-economic model simulation based on a patient survey and clinical trial data. Br J Dermatol. 2007;156:913-921. (Pubitemid 46642804)
6. Coyle D, Barbeau M. Cost effectiveness of Elidel in the management of patients with atopic dermatitis in Canada. J Cutaneous Med Surg. 2004;8:405-410. (Pubitemid 41414108)
7. Soter NA, Fleischer AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II; Safety. J Am Acad Dermatol. 2001;44:S39-S46. (Pubitemid 32047912)
8. Drug Topics Redbook. Monvale, NJ: Medical Economics, Inc. 2007.
9. Medicare Resource-Base Relative Value Scale 2007. Chicago, III: American Medication Association 2007.
10. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: Randomized, double blind, parallel group study. BMJ. 2003;326(7403):1367.